Heterogeneous treatment effects in stratified clinical trials with time‐to‐event endpoints (Q5348691): Difference between revisions

From MaRDI portal
Created claim: Wikidata QID (P12): Q38927246, #quickstatements; #temporary_batch_1711574657256
Normalize DOI.
 
(One intermediate revision by one other user not shown)
Property / DOI
 
Property / DOI: 10.1002/bimj.201600047 / rank
Normal rank
 
Property / cites work
 
Property / cites work: The frailty model. / rank
 
Normal rank
Property / cites work
 
Property / cites work: Q4741623 / rank
 
Normal rank
Property / cites work
 
Property / cites work: Evaluation of Sample Size and Power for Analyses of Survival with Allowance for Nonuniform Patient Entry, Losses to Follow-Up, Noncompliance, and Stratification / rank
 
Normal rank
Property / cites work
 
Property / cites work: Sample-Size Formula for the Proportional-Hazards Regression Model / rank
 
Normal rank
Property / cites work
 
Property / cites work: The asymptotic theory of permutation statistics. / rank
 
Normal rank
Property / DOI
 
Property / DOI: 10.1002/BIMJ.201600047 / rank
 
Normal rank

Latest revision as of 17:44, 30 December 2024

scientific article; zbMATH DE number 6762403
Language Label Description Also known as
English
Heterogeneous treatment effects in stratified clinical trials with time‐to‐event endpoints
scientific article; zbMATH DE number 6762403

    Statements

    Heterogeneous treatment effects in stratified clinical trials with time‐to‐event endpoints (English)
    0 references
    0 references
    0 references
    0 references
    0 references
    18 August 2017
    0 references
    biomarkers
    0 references
    Cox proportional hazards model
    0 references
    log-rank test
    0 references
    sample size
    0 references
    shared frailty model
    0 references
    trial design
    0 references

    Identifiers

    0 references
    0 references
    0 references
    0 references
    0 references
    0 references
    0 references